Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Oral Doses of SLx-2119 in Healthy Male Subjects
NCT05918627Phase 1Completed
- Sponsor
- Sanofi
- Start
- Sep 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of belumosudil in chronic graft-versus-host disease (cGVHD) (6 arms), sponsored by Sanofi. Primary endpoint: Number of participants with adverse events and serious adverse events. Started Sep 2009; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT05918627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918627.